<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603245022
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Roxban
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        179.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Roxban contains the active substance rivaroxaban and is used in adults to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prevent blood clots in brain (stroke) and other blood vessels in your body if you have a form of irregular heart rhythm called non-valvular atrial fibrillation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.</p><p>&nbsp;</p><p>Roxban belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Roxban</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are bleeding excessively</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver disease which leads to an increased risk of bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or are breast-feeding</p><p>Do not take Roxban and tell your doctor if any of these apply to you.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Roxban.</p><p>&nbsp;</p><p><strong>Take special care with Roxban</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if you have an increased risk of bleeding, as could be the case in situations such as:</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe kidney disease, since your kidney function may affect the amount of medicine that works in your body</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open<strong><em>&nbsp;</em></strong>(see section &ldquo;Other medicines and Roxban&rdquo;)</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very high blood pressure, not controlled by medical treatment</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus) or tumours located in the stomach or bowels or genital tract or urinary tract</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if you have a prosthetic heart valve</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned</p><p>&nbsp;</p><p>If any of the above apply to you, tell your doctor before you take Roxban. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>&nbsp;</p><p><strong>If you need to have an operation</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it is very important to take Roxban before and after the operation exactly at the times you have been told by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):</p><p>&sect;&nbsp;&nbsp;it is very important to take Roxban before and after the injection or removal of the catheter exactly at the times you have been told by your doctor</p><p>&sect;&nbsp;&nbsp;tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Roxban is not recommended for people under 18 years of age.</p><p>There is not enough information on its use in children and adolescents.</p><p><em>&nbsp;</em></p><p><strong>Other medicines and Roxban</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are taking</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;ketoconazole tablets (used to treat Cushing&rsquo;s syndrome - when the body produces an excess of cortisol)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;some medicines for bacterial infections (e.g. clarithromycin, erythromycin)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some anti-viral medicines for HIV&nbsp;/ AIDS (e.g. ritonavir)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin&nbsp;K antagonists such as warfarin and acenocoumarol)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dronedarone, a medicine to treat abnormal heart beat</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))</p><p><strong>&nbsp;</strong></p><p>If any of the above apply to you, tell your doctor before taking Roxban, because the effect of Roxban may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are taking</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (Hypericum perforatum), a herbal product used for depression</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, an antibiotic</p><p>&nbsp;</p><p>If any of the above apply to you, tell your doctor before taking Roxban, because the effect of Roxban may be reduced. Your doctor will decide, if you should be treated with Roxban and if you should be kept under closer observation.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not take Roxban if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Roxban. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Roxban may cause dizziness (common side effect) or fainting (uncommon side effect) (see section&nbsp;4, &rdquo;Possible side effects&rdquo;). You should not drive, ride a bicycle or use any tools or machines if you are affected by these symptoms.</p><p>&nbsp;</p><p><strong>Roxban contains lactose and sodium</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p>You must take Roxban together with a meal.</p><p>Swallow the tablet(s) preferably with water.</p><p>&nbsp;</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Roxban. The tablet may be crushed and mixed with water or apple puree immediately before you take it. This mixture should be immediately followed by food.</p><p>If necessary, your doctor may also give you the crushed Roxban tablet through a stomach tube.</p><p><strong>&nbsp;</strong></p><p><strong>How much to take</strong></p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;To prevent blood clots in brain (stroke) and other blood vessels in your body</p><p>The recommended dose is one tablet Roxban 20&nbsp;mg once a day.</p><p>If you have kidney problems, the dose may be reduced to one tablet Roxban 15&nbsp;mg once a day.</p><p>&nbsp;</p><p>If you need a procedure to treat blocked blood vessels in your heart (called a percutaneous coronary intervention - PCI with an insertion of a stent), there is limited evidence to reduce the dose to one tablet Roxban 15&nbsp;mg once a day (or to one tablet Roxban 10&nbsp;mg once a day in case your kidneys are not working properly) in addition to an antiplatelet medicine such as clopidogrel.</p><p>&nbsp;</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring</p><p>The recommended dose is one tablet Roxban 15&nbsp;mg twice a day for the first 3&nbsp;weeks. For treatment after 3&nbsp;weeks, the recommended dose is one tablet Roxban 20&nbsp;mg once a day.</p><p>After at least 6 months blood clot treatment your doctor may decide to continue treatment with either one 10 mg tablet once a day or one 20 mg tablet once a day.</p><p>If you have kidney problems and take one tablet Roxban 20 mg once a day, your doctor may decide to reduce the dose for the treatment after 3 weeks to one tablet Roxban 15 mg once a day if the risk for bleeding is greater than the risk for having another blood clot.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>When to take Roxban</strong></p><p>Take the tablet(s) every day until your doctor tells you to stop.</p><p>Try to take the tablet(s) at the same time every day to help you to remember it.</p><p>Your doctor will decide how long you must continue treatment.</p><p>&nbsp;</p><p>To prevent blood clots in the brain (stroke) and other blood vessels in your body:</p><p>If your heart beat needs to be restored to normal by a procedure called cardioversion, take Roxban at the times your doctor tells you.</p><p>&nbsp;</p><p><strong>If you take more Roxban than you should</strong></p><p>Contact your doctor immediately if you have taken too many Roxban tablets. Taking too much Roxban increases the risk of bleeding.</p><p>&nbsp;</p><p><strong>If you forget to take Roxban</strong></p><p>If you are taking one 20&nbsp;mg tablet or one 15&nbsp;mg tablet&nbsp;<strong>once</strong>&nbsp;a day and have missed a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet on the following day and then carry on taking one tablet once a day.</p><p>&nbsp;</p><p>If you are taking one 15&nbsp;mg tablet&nbsp;<strong>twice</strong>&nbsp;a day and have missed a dose, take it as soon as you remember. Do not take more than two 15&nbsp;mg tablets in a single day. If you forget to take a dose you can take two 15&nbsp;mg tablets at the same time to get a total of two tablets (30&nbsp;mg) on one day. On the following day you should carry on taking one 15&nbsp;mg tablet twice a day.</p><p>&nbsp;</p><p><strong>If you stop taking Roxban</strong></p><p>Do not stop taking Roxban without talking to your doctor first, because Roxban treats and prevents serious conditions.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Roxban can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Like other similar medicines to reduce the formation of blood clots, Roxban may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately if you experience any of the following side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Signs of bleeding</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding into the brain or inside the skull (symptoms can include headache, one-sided weakness, vomiting, seizures, decreased level of consciousness, and neck stiffness.<br />A serious medical emergency. Seek medical attention immediately!)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long or excessive bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may decide to keep you under closer observation or change the treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Signs of severe skin reactions</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a drug reaction that causes rash, fever, inflammation of internal organs, blood abnormalities and systemic illness (DRESS syndrome).</p><p>The frequency of these side effects is very rare (up to 1 in 10,000&nbsp;people).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Signs of severe allergic reactions</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure.</p><p>The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000&nbsp;people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100&nbsp;people).</p><p>&nbsp;</p><p><strong>Overall list of possible side effects</strong></p><p><strong>Common&nbsp;</strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding into the eye (including bleeding from the whites of the eyes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding into tissue or a cavity of the body (haematoma, bruising)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;coughing up blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding from the skin or under the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding following an operation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oozing of blood or fluid from surgical wound</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;swelling in the limbs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pain in the limbs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impaired function of the kidneys (may be seen in tests performed by your doctor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stomach ache, indigestion, feeling or being sick, constipation, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;low blood pressure (symptoms may be feeling dizzy or fainting when standing up)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;decreased general strength and energy (weakness, tiredness), headache, dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rash, itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;blood tests may show an increase in some liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon&nbsp;</strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding into the brain or inside the skull (see above, signs of bleeding)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding into a joint causing pain and swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;thrombocytopenia (low number of platelets, which are cells that help blood to clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;allergic reactions, including allergic skin reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impaired function of the liver (may be seen in tests performed by your doctor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;feeling unwell</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;faster heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;hives</p><p>&nbsp;</p><p><strong>Rare&nbsp;</strong>(may affect up to 1 in 1,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding into a muscle</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;yellowing of the skin and eye (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;localised swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)</p><p>&nbsp;</p><p><strong>Very rare</strong>&nbsp;(may affect up to 1 in 10,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accumulation of eosinophils, a type of white granulocytic blood cells that cause inflammation in the lung (eosinophilic pneumonia)</p><p>&nbsp;</p><p><strong>Not known&nbsp;</strong>(frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;kidney failure after a severe bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Keep this medicine out of the sight and reach of children.</p><p>- Do not use this medicine after the expiry date which is stated on carton, bottle and blister foil after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>- Do not store above 30&deg;C</p><p>-Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste.</p><p>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>What Roxban contains </u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Roxban 15 mg Filmcoated Tablets:</p><p>The active substance is Rivaroxaban. Each tablets contains Microcrystalline Cellulose, Croscarmellose sodium, Lactose Monohydrate, Hypromellose, Sodium Laurilsulfate, Magnesium Stearate, Coating material for 15 mg Opadry Red 03F250004.</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Roxban 20 mg Filmcoated Tablets:</p><p>The active substance is Rivaroxaban. Each tablets contains Microcrystalline Cellulose, Croscarmellose sodium, Lactose Monohydrate, Hypromellose, Sodium Laurilsulfate, Magnesium Stearate, Coating material for 20 mg Opadry Red 03F250005.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Roxban15 mg film coated tablets supplied as red, round, bi-convex film-coated tablets, engraved with “15” on one side, plain on the other side.

Roxban20 mg film coated tablets supplied as brown red, round, bi-convex film-coated tablets, plain on both sides.

Roxban 15,20 mg available in blister packs containing 30 tablets in one unit cartoon.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong>:</p><p>AJA Pharmaceutical Industries Company Ltd.,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hail Industrial City MODON, Street No 32</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PO Box 6979, Hail 55414</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kingdom of Saudi Arabia.</p><p><strong>&nbsp; Manufacturer: </strong></p><p>AJA Pharmaceutical Industries Company Ltd.,</p><p>Hail Industrial City MODON, Street No 32</p><p>PO Box 6979, Hail 55414</p><p>Kingdom of Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This Leaflet approved in August 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي روكسبان على المادة الفعالة ريفاروكسابان ويستخدم لدى المرضى البالغين لعلاج الحالات التالية:</p><p dir="RTL"><strong>منع حدوث الجلطات الدموية في الدماغ (المخ) (السكتة) و الأوعية الدموية الأخرى في الجسم</strong>&nbsp;إذا كان لديك شكل من أشكال عدم انتظام ضربات القلب التي تسمى&nbsp;<strong>رجفان أذيني غير صمامي.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>علاج الجلطات الدموية&nbsp;</strong>في أوردة السيقان<strong>&nbsp;(خثار وريدي عميق)&nbsp;</strong>و في الأوعية الدموية للرئة&nbsp;<strong>(الانسداد الرئوي)، و لمنع تكرار حدوث الجلطات الدموية</strong>&nbsp;في الأوعية الدموية للسيقان و / أو الرئة.</p><p dir="RTL">ينتمي روكسبان لملجموعة من الأدوية تسمى&nbsp;<strong>عوامل مانعة الخثار&nbsp;</strong>(مانعة للتجلط).يُحدث مفعول معّوق لعامل تجلط الدم (عامل Xa) و بالتالي يقلل ميل الدم لتكوين جلطات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2 .ما يجب عليك معرفته قبل تناول </strong><strong>روكسبان</strong><strong>&nbsp;&nbsp; </strong></p><p><strong>موانع استعمال روكسبان</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كان لديك حساسية للريفاروكسابان أو لأي من المكونات الأخرى في هذا الدواء (المدونة في الجزء 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كنت تنزف بإفراط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كان لديك مرض أو حالة جهاز أحد أجهزة الجسم تزيد من خطر النزف الخطير (مثال لذلك قرحة المعدة، إصابة أو نزف في الدماغ، جراحة حديثة للدماغ أو العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كنت تتناول أدوية لمنع تجلط الدم (مثل الوارفارين، دبيجاتران، ابيكسابان أو هيبارين)، ما عدا عند تغيير العلاج المضاد للتجلط أو خلال استخدام الهيبارين عن طريق انبوب تسريب داخل الوريد أو الشريان لإبقائه مفتوحاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كان لديك مرض في الكبد الذي يؤدي إلى زيادة مخاطرة النزف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كنتِ حامل أو ترضعين طبيعياً</p><p dir="RTL"><strong>لا تتناول روكسبان و ابلغ طبيبك</strong>&nbsp;إذا كان أي من هذه الحالات تنطبق عليك.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي قبل تناول روكسبان.</p><p dir="RTL"><strong>اتخذ عناية خاصة مع روكسبان</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كان لديك خطر متزايد للنزف، كما يمكن أن يكون هذا هو الحال في حالات مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;أمراض الكلى الشديدة، لأن وظيفة الكلى قد تؤثر على كمية الدواء التي تعمل في جسمك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;إذا كنت تتناول أدوية اخرى لمنع تجلط الدم (مثل الوارفارين، دبيجاتران، ابيكسابان أو هيبارين)، عندما يتم تغيير العلاج المضاد للتجلط أو خلال استخدام الهيبارين عن طريق انبوب تسريب داخل الوريد أو الشريان لإبقائه مفتوحاً (انظر الجزء &laquo;تناول أدوية أخرى مع روكسبان&raquo;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;اضطرابات نزف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;ضغط دم مرتفع جداً، غير منضبط بعلاج طبي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;أمراض المعدة أو الأمعاء التي قد تؤدي إلى النزف، على سبيل المثال التهاب الأمعاء أو المعدة، أو التهاب في المريء (المريء) على سبيل المثال بسبب مرض الارتداد المعدي المريئي (يحدث في هذا المرض أن حمض المعدة يصعد إلى المريء) أو الأورام الموجودة في المعدة أو الأمعاء أو المسالك التناسلية أو المسالك البولية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;مشكلة بالأوعية الدموية خلف العيون (اعتلال الشبكية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;مرض للرئة، يسبب توسيع للشعب الهوائية الخاصة بك و تمتلئ بالصديد (توسع القصبات)، أو حدوث نزف سابق من رئتك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كان لديك صمام صناعي في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كنت تعلم أن لديك مرضاً يسمى متلازمة مضاد الفوسفوليبيد (اضطراب في الجهاز المناعي الذي يسبب زيادة خطر جلطات الدم) ، أخبر طبيبك الذي سيقرر ما إذا كان العلاج قد يحتاج إلى تغيير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا حدد طبيبك أن ضغط الدم غير مستقر أو من المقرر تناول علاج آخر أو إجراء عملية جراحية لإزالة الدم المتجلط من الرئتين</p><p dir="RTL"><strong>أبلغ طبيبك</strong>&nbsp;قبل ان تتناول روكسبان، إذا كان اي من هذه الحالات تنطبق عليك. سوف يقرر طبيبك، إذا كان يجب أن تعالج بهذا الدواء و إذا كان يجب أن يبقيك تحت ملاحظة أدق.</p><p dir="RTL"><strong>إذا كنت في حاجة لإجراء عملية جراحية:</strong></p><p dir="RTL">من الهام جداً أن يتم تناول روكسبان قبل و بعد العملية الجراحية تماماً في الأوقات التي أوصي بها طبيبك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كانت العملية تتضمن قسطرة أو حقن في العمود الفقري (مثل تخدير فوق الجافية أو النخاع الشوكي أو للحد من الألم):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;من المهم جدا أن تتناول روكسبان قبل وبعد الحقن أو إزالة القسطرة في الأوقات المحددة التي أوصي بها طبيبك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;أخبر طبيبك فورا اذا كان لديك تنميل أو ضعف في الساقين أو مشاكل بالأمعاء أو المثانة بعد انتهاء التخدير، لأنه من الضروري وجود رعاية عاجلة</p><p dir="RTL"><strong>الاطفال و المراهقين</strong></p><p dir="RTL"><strong>لا يوصى بتناول روكسبان لأشخاص عمرهم أقل من 18 سنة.</strong>&nbsp;لا توجد معلومات كافية عن استخدامه لدى الأطفال و المراهقين.</p><p dir="RTL"><strong>تناول أدوية أخرى مع روكسبان</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت حديثاً أو قد تتناول أية أدوية أخرى، بما فيها الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>إذا كنت تتناول:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;بعض الأدوية للعدوى الفطرية (مثل فلوكونازول، إيتراكونازول، فوريكونازول، بوزاكونازول)، إلا إذا وضعت فقط على الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;أقراص الكيتوكونازول (المستخدمة لعلاج متلازمة كوشينغ - عندما ينتج الجسم فائض من الكورتيزول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;بعض أدوية العدوى البكتيرية (مثل كلاريثرومايسين وإريثروميسين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;بعض الأدوية المضادة للفيروسات لفيروس النقص المناعي البشري / الإيدز (متلازمة النقص المناعي المكتسب) HIV / AIDS (مثل ريتونافير)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;أدوية أخرى لتقليل تجلط الدم (على سبيل المثال إنوكسابارين، كلوبيدوجرل أو مضادات فيتامين ك مثل الوارفارين و الاسينوكومارول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;أدوية مضادة للإلتهاب و مسكنة للألم (مثل نابروكسين أو حامض الاسيتيل ساليسيليك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;دروندارون، دواء لعلاج ضربات القلب الغير طبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;بعض الأدوية لعلاج الاكتئاب (مثبطات امتصاص السيروتونين الانتقائية (SSRIs) أو مثبطات امتصاص النوربينفرين سيروتونين (SNRIs))</p><p dir="RTL"><strong>ابلغ طبيبك قبل استخدام روكسبان إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك،</strong>&nbsp;لأن تأثير روكسبان يمكن أن يزداد. سوف يقرر طبيبك، إذا كان يجب علاجك بالروكسبان و إذا كان يجب أن يبقيك تحت ملاحظة دقيقة.</p><p dir="RTL">إذا كان طبيبك يعتقد أن هناك خطورة حدوث قرح في المعدة أو في الأمعاء، يمكنه أيضاً استخدام علاج وقائي للقرحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>إذا كنت تتناول:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;بعض الأدوية لعلاج الصرع (فنيتوين، كاربامازبين، فينوباربيتال).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;عشبة القديس جون، منتج نباتي يتم استخدامه لعلاج الاكتئاب،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;ريفامبسين، مضاد حيوي.</p><p dir="RTL"><strong>ابلغ طبيبك قبل تناول روكسبان، إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك،</strong>&nbsp;لأن تأثير روكسبان يمكن أن يقل. سوف يقرر طبيبك، إذا كان يجب علاجك بروكسبان و إذا كان يجب أن يبقيك تحت ملاحظة دقيقة.</p><p dir="RTL"><strong>الحمل و الرضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي روكسبان، إذا كنتِ حامل أو ترضعين طبيعياً.إذا كان هناك احتمال بأن تصبحي حاملا، استخدمي مانع للحمل مضمون أثناء تناولك روكسبان. إذا أصبحتِ حاملا أثناء استخدامك روكسبان، فوراً اخطري طبيبك الذي سوف يقرر كيف يجب علاجك.</p><p dir="RTL"><strong>القيادة و استخدام الماكينات</strong></p><p dir="RTL">يمكن أن يسبب روكسبان دوخة (آثار جانبية شائعة) أو إغماء (آثار جانبية غير شائعة) (أنظر الجزء 4 &laquo;الآثار الجانبية المحتملة&raquo;). يجب عدم القيادة، ركوب دراجة أو استخدام أي أدوات أو ماكينات إذا عانيت من هذه الأعراض.</p><p dir="RTL"><strong>يحتوي روكسبان على اللاكتوز و الصوديوم.</strong></p><p dir="RTL">إذا كان قد تم إبلاغك من قبل الطبيب أن لديك عدم احتمال لبعض السكريات، اتصل بطبيبك قبل تناول روكسبان.</p><p dir="RTL">يحتوي كل قرص من هذا الدواء على أقل من 1 مللي مول صوديوم (23 ملجم)، وهذا يعني بشكل أساسي انه &laquo;خالٍ من الصوديوم&raquo;.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول هذا الدواء بدقة كما يوصي به طبيبك.</p><p dir="RTL">إذا كنت غير متأكد يجب المراجعة مع طبيبك أو الصيدلي.</p><p dir="RTL"><strong>يجب أن تتناول روكسبان مع الطعام.</strong></p><p dir="RTL">يُفضل أن يُبلع القرص مع الماء.</p><p dir="RTL">إذا كان لديك صعوبة في بلع القرص بأكمله، أبلغ طبيبك عن طرق أخرى لتناول روكسبان.</p><p dir="RTL">يمكن سحق الأقراص و خلطها مع الماء أو التفاح المهروس مباشرة قبل تناولها. ينبغي تناول الطعام مباشرة بعد تناول هذا الخليط.</p><p dir="RTL">إذا لزم الأمر، قد يعطيك أيضاً طبيبك مسحوق قرص روكسبان عن طريق أنبوب في المعدة.</p><p dir="RTL"><strong>ما هي الكمية التي يجب تناولها</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;لمنع الجلطات الدموية في الدماغ (السكتة الدماغية) و الأوردة الدموية الأخرى في الجسم</p><p dir="RTL">الجرعة الموصي بها هي قرص واحد روكسبان 20 ملجم مرة واحدة يومياً.</p><p dir="RTL">إذا كان لديك مشاكل في الكلى، يمكن تخفيض الجرعة لقرص واحد روكسبان 15 ملجم مرة واحدة يومياً.</p><p dir="RTL">إذا كنت بحاجة إلى إجراء لعلاج الأوعية الدموية المسدودة في قلبك (وتسمى التدخل التاجي عن طريق الجلد (PCI)&nbsp; مع إدخال الدعامات)، هناك أدلة محدودة لتقليل الجرعة إلى قرص واحد من الروكسبان 15 ملجم مرة واحدة يوميا (أو قرص واحد</p><p dir="RTL">روكسبان 10 ملجم مرة واحدة يوميا في حالة أن الكليتين لا تعملان بشكل سليم) بالإضافة إلى منتج طبي مضاد للصفيحات (الصفائح الدموية) مثل كلوبيدوغريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;لعلاج الجلطات الدموية في أوردة السيقان و الجلطات الدموية في الأوعية الدموية للرئة، و لمنع تكرار حدوث جلطات دموية</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد روكسبان 15 ملجم مرتين يومياً للـ 3 أسابيع الأولى. العلاج بعد 3 أسابيع، الجرعة الموصي بها هي قرص واحد روكسبان 20 ملجم مرة واحدة يومياً.</p><p dir="RTL">بعد 6 أشهر على الأقل من علاج جلطة الدم، قد يقرر طبيبك مواصلة العلاج إما قرص واحد روكسبان 10 ملجم مرة واحدة يومياً أو قرص واحد روكسبان 20 ملجم مرة واحدة يومياً.</p><p dir="RTL">إذا كان لديك مشاكل في الكلى و تعالج بقرص واحد روكسبان 20 ملجم مرة واحدة يومياً، يمكن لطبيبك أن يقرر تخفيض الجرعة للعلاج بعد ثلاثة أسابيع إلى قرص واحد روكسبان 15 ملجم مرة واحدة في اليوم إذا كانت مخاطرة النزف أكبر من مخاطرة حدوث جلطة دموية أخرى.</p><p dir="RTL"><strong>متى يتم تناول روكسبان</strong></p><p dir="RTL">تناول القرص (الأقراص) كل يوم حتى يخبرك الطبيب بالتوقف.</p><p dir="RTL">حاول أن تتناول القرص (الأقراص) في نفس الموعد كل يوم لمساعدتك على أن تتذكره.</p><p dir="RTL">سوف يقرر طبيبك إلى متى يجب مواصلة العلاج.</p><p dir="RTL">لمنع تجلط الدم في الدماغ (سكتة دماغية) والأوعية الدموية الأخرى في الجسم.</p><p dir="RTL">إذا كانت ضربات قلبك تحتاج إلى إعادتها إلى وضعها الطبيعي (إعادة تنظيمها) من خلال إجراء يسمى تقويم نظم القلب، تناول روكسبان في الأوقات التي يحددها طبيبك.</p><p dir="RTL"><strong>إذا تناولت روكسبان أكثر مما ينبغي تناوله</strong></p><p dir="RTL">اتصل بطبيبك فوراً إذا كنت قد تناولت أقراص روكسبان أكثر مما ينبغي بكثير.</p><p dir="RTL">تناول روكسبان بكميات كبيرة يزيد خطر النزف.</p><p dir="RTL"><strong>إذا نسيت تناول روكسبان</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كنت تتناول قرص واحد 20 ملجم أو قرص واحد 15 ملجم مرة واحدة و نسيت الجرعة، تناولها فوراً بمجرد تذكرها. لا تتناول أكثر من قرص واحد في اليوم الواحد لتعويض جرعة منسية. تناول القرص التالي في اليوم التالي و بعد ذلك استمر في تناول قرص مرة واحدة يومياً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إذا كنت تتناول قرص واحد 15 ملجم مرتين يومياً و نسيت الجرعة، تناولها فوراً بمجرد تذكرها. لا تتناول أكثر من قرصين 15 ملجم في اليوم الواحد. إذا نسيت تناول جرعة، يمكنك أن تتناول قرصين 15 ملجم في نفس الوقت للحصول على ملجموع قرصين</p><p dir="RTL">(30 ملجم) في يوم واحد. في اليوم التالي يجب أن تستمر في تناول قرص واحد 15 ملجم مرتين يومياً.</p><p dir="RTL"><strong>إذا توقفت عن استخدام روكسبان</strong></p><p dir="RTL">لا تتوقف عن استخدام روكسبان بدون مناقشة ذلك مع طبيبك اولاً، لأن روكسبان يعالج و يمنع تطور الحالات الخطيرة.</p><p>إذا كان لديك اسئلة إضافية عن استخدام هذا المستحضر، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، روكسبان يمكن أن يسبب آثارا جانبية، على الرغم أنه ليس كل شخص يصاب بها.</p><p dir="RTL">مثل الأدوية الأخرى المماثلة لتقليل تكوين جلطات الدم، قد يتسبب روكسبان في حدوث نزيف قد يكون مهددًا للحياة. النزف الزائد يمكن أن يؤدي لهبوط مفاجيء في ضغط الدم (صدمة). في بعض الحالات يمكن للنزف أن يكون غير واضح.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أبلغ طبيبك فوراً إذا عانيت اي من الآثار الجانبية الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>علامات النزيف</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;نزيف في الدماغ أو داخل الجملجمة (يمكن أن تشمل الأعراض الصداع والضعف من جانب واحد والقيء والنوبات (تشنجات) وانخفاض مستوى الوعي وتيبس الرقبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;هذه حالة طبية طارئة خطيرة. اطلب العناية الطبية على الفور!)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;نزف لفترة طويلة أو مفرط (غزير)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;ضعف غير اعتيادي، تعب، شحوب، دوخة، صداع، تورم غير مبرر، صعوبة التنفس، ألم في الصدر أو ذبحة صدرية،</p><p dir="RTL">ربما يقرر طبيبك أن يبقيك تحت ملاحظة دقيقة أو يغير العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>علامات ردود فعل جلدية شديدة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;انتشار طفح جلدي شديد، بثور أو آفات مخاطية، على سبيل المثال. في الفم أو العينين (متلازمة ستيفنز جونسون / انحلال البشرة السام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;تفاعل دوائي يسبب الطفح الجلدي والحمى والتهاب الأعضاء الداخلية والشذوذ الدموي والأمراض الجهازية (متلازمة DRESS).</p><p dir="RTL">تكرار هذه التأثيرات الجانبية نادر جدا (يصل إلى 1 في 10,000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>علامات ردود فعل حساسية شديدة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;تورم في الوجه، الشفتين، الفم، اللسان أو الحلق؛ صعوبة في البلع؛ حكة موضعية وصعوبات في التنفس؛ انخفاض مفاجئ في ضغط الدم.</p><p dir="RTL">تكرار ردود فعل الحساسية الشديدة نادر جداً (ردود أفعال لحساسية مبالغ فيها، بما في ذلك صدمة الحساسية؛ يمكن أن تصل الإصابة إلى 1 في 10,000 شخص) وغير شائع (تورم لمنطقة في الطبقة السفلى من الجلد والأنسجة التي تقع تحت الجلد أو الأغشية المخاطية والتراكم المفرط للسوائل، وخاصة الماء، في فراغات أنسجة الجسم بسبب الحساسية؛ يمكن أن تصل الإصابة إلى 1 في 100 شخص)</p><p dir="RTL"><strong>قائمة كاملة للآثار الجانبية المحتملة:</strong></p><p dir="RTL"><strong>شائعة&nbsp;</strong>(يمكن أن تصيب حتى 1 في10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;انخفاض في خلايا الدم الحمراء التي يمكن أن تجعل الجلد شاحب و تسبب ضعف أو صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف في المعدة أو الأمعاء، نزف في الجهاز البولي و التناسلي (تشمل دم في البول و نزف حيضي / دورة شهرية شديدة)، نزف بالانف، نزف باللثة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف داخل العين (يشمل نزف من بياض العيون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف داخل نسيج أو تجويف في الجسم (تجمع دموي، تكدم (كدمة))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;سعال مصاحب لدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف من الجلد أو تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف بعد اجراء عملية جراحية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ارتشاح دم أو سائل من الجرح الجراحي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تورم في الاطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ألم في الاطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;خلل في وظائف الكلى (يمكن التعرف عليها في الاختبارات التي يؤديها الطبيب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ارتفاع في درجة حرارة الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ألم في المعدة، عسر الهضم، شعور بالغثيان، إمساك، إسهال،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ضغط دم منخفض (الأعراض يمكن أن تكون دوخة أو إغماء عند الوقوف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;انخفاض عام في المقدرة و الطاقة (ضعف، تعب)، صداع، دوخة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;طفح، حكة جلدية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;يمكن أن تُظهر اختبارات الدم زيادة في بعض إنزيمات الكبد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة&nbsp;</strong>(يمكن أن تصيب حتى 1 في 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف داخل المخ أو داخل الجملجمة (انظر اعلاه - علامات النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف داخل المفصل يسبب ألم و ورم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نقص الصفيحات (انخفاض عدد الصفائح الدموية، وهي الخلايا التي تساعد على تجلط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تفاعلات أرجية (حساسية)، تشمل تفاعلات أرجية (حساسية) للجلد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;خلل وظائف الكبد (يمكن أن يظهر في الفحوصات المخبرية الذي يقوم بها طبيبك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;يمكن أن تُظهر اختبارات الدم زيادة في البيليروبين، بعض إنزيمات البنكرياس أو إنزيمات الكبد أو في عدد الصفيحات الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;شعور باعتلال الصحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;زيادة ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;جفاف بالفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;شرى (ارتكاريا)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادراً&nbsp;</strong>(يمكن أن تصيب حتى 1 في 1,000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;نزف داخل العضل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ركود صفراوي (انخفاض تدفق الصفراء)، التهاب الكبد بما في ذلك إصابة الخلايا الكبدية (التهاب الكبد بما في ذلك إصابة الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;اصفرار الجلد و العين (يرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تورم موضعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تجمع دموي (ورم دموي) في الفخذ كمضاعفات لإجراءات قلبية تتطلب إدخال قسطرة (قثطار) داخل شريان الساق (تمدد كيسى دموى كاذب)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة جدًا&nbsp;</strong>(قد تظهر لدى حتى 1 من بين 10.000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تراكم الحمضات ، وهي نوع من خلايا الدم البيضاء المحببة التي تسبب التهابًا في الرئة (الالتهاب الرئوي اليوزيني)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة&nbsp;</strong>(لا يمكن تقدير تكرارها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;فشل كلوي بعد نزف شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ارتفاع الضغط&nbsp; داخل عضلات السيقان أو الأذرع بعد النزف، و الذي يمكن أن يؤدي لألم، تورم، تغيير في الاحساس، تنميل أو شلل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حفظ هذا الدواء بعيدًا عن مرأى ومتناول أيدي الأطفال.</p><p dir="RTL">&nbsp;- لا تستخدم هذا المستحضر بعد تاريخ انتهاء الصلاحية المدون على العبوة الخارجية والملصق بعد الرمز &quot;EXP&quot; الذي يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">- يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">- لا تستخدم هذا المستحضر إذا لاحظت أن العبوة تالفة أو تظهر عليها علامات العبث.</p><p dir="RTL">&nbsp;-لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية.</p><p dir="RTL">اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير على حماية البيئة.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>ما هي محتويات روكسبان </u></p><p dir="RTL">روكسبان15 ملجم أقراص مغلفة:</p><p dir="RTL">المادة الفعالة هي ريفاروكسابان. يحتوي كل قرص على مايكروكرستلين سيليلوز ، كروسكارميلوز صوديوم ، لاكتوز مونوهيدريت ، هيبروميلوز ، صوديوم لوريل سلفيت ، مغنيسيوم سيتيريت ، أوبادري (أحمر &nbsp;03F250004).</p><p dir="RTL">روكسبان20 ملجم أقراص مغلفة:</p><p dir="RTL">المادة الفعالة هي ريفاروكسابان. يحتوي كل قرص على مايكروكرستلين سيليلوز ، كروسكارميلوز صوديوم ، لاكتوز مونوهيدريت ، هيبروميلوز ، صوديوم لوريل سلفيت ، مغنيسيوم سيتيريت ، أوبادري (أحمر &nbsp;03F250005).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>كيف يبدو المنتج وما هي محتويات العبوة </u></p><p dir="RTL">روكسبان15 ملجم أقراص مغلفة متوفرة على شكل أقراص حمراء ، مستديرة ، ثنائية التحدب ، مغلفة بطبقة رقيقة ، منقوشة &nbsp;بـ &quot;15&quot; على جانب واحد فقط.</p><p dir="RTL">روكسبان20 ملجم أقراص مغلفة متوفرة على شكل أقراص حمراء بنية ، مستديرة ، ثنائية التحدب ، مغلفة بطبقة رقيقة ، منقوشة &nbsp;بـ &quot;20&quot; سادة من الجهتين.&nbsp;</p><p>روكسبان15،20 ملجم متوفر في عبوات بها شرائط تحتوي على 30 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق </strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">المدينة الصناعية مدن بحائل ، شارع رقم 32</p><p dir="RTL">ص.ب. 6979، حائل 55414</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">المدينة الصناعية مدن بحائل ، شارع رقم 32</p><p dir="RTL">ص.ب. 6979، حائل 55414</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذة النشرة في أغسطس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROXBAN 15 mg and 20 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROXBAN 15 mg tablets Each film coated tablet contains 15 mg of Rivaroxaban
ROXBAN 20 mg tablets Each film coated tablet contains 20 mg of Rivaroxaban

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROXBAN 15 mg tablet:
Red, round, bi-convex film-coated tablets, engraved with “15” on one side, plain on the other side
ROXBAN 20 mg tablet:
Brown Red, round, bi-convex film-coated tablets, plain on both sides

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age &ge;&nbsp;75&nbsp;years, diabetes mellitus, prior stroke or transient ischaemic attack.</p><p>&nbsp;</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section&nbsp;4.4 for haemodynamically unstable PE patients.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p><em>Prevention of stroke and systemic embolism</em></p><p>The recommended dose is 20&nbsp;mg once daily, which is also the recommended maximum dose.</p><p>&nbsp;</p><p>Therapy with Roxban should be continued long term provided the benefit of prevention of stroke and systemic embolism outweighs the risk of bleeding (see section&nbsp;4.4).</p><p>&nbsp;</p><p>If a dose is missed the patient should take Roxban immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p>&nbsp;</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE</em></p><p>The recommended dose for the initial treatment of acute DVT or PE is 15&nbsp;mg twice daily for the first three weeks followed by 20&nbsp;mg once daily for the continued treatment and prevention of recurrent DVT and PE.</p><p>&nbsp;</p><p>Short duration of therapy (at least 3&nbsp;months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.&nbsp;</p><p>&nbsp;</p><p>When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6&nbsp;months therapy for DVT or PE), the recommended dose is 10&nbsp;mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those&nbsp;with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Roxban 10&nbsp;mg once daily, a dose of Roxban 20&nbsp;mg once daily should be considered.</p><p>&nbsp;</p><p>The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section&nbsp;4.4).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Time period</strong></p></td><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:top"><p><strong>Total daily dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Treatment and prevention of recurrent DVT and PE</p></td><td style="vertical-align:top"><p>Day 1 - 21</p></td><td style="vertical-align:top"><p>15 mg twice daily</p></td><td style="vertical-align:top"><p>30 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 22 onwards</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of recurrent DVT and PE</p></td><td style="vertical-align:top"><p>Following completion of at least 6 months therapy for DVT or PE</p></td><td style="vertical-align:top"><p>10 mg once daily or</p><p>20 mg once daily</p></td><td style="vertical-align:top"><p>10 mg</p><p>or 20 mg</p></td></tr></tbody></table><p>To support the dose switch from 15&nbsp;mg to 20&nbsp;mg after Day 21 a first 4&nbsp;weeks treatment initiation pack of Roxban for treatment of DVT/PE is available.</p><p>&nbsp;</p><p>If a dose is missed during the 15&nbsp;mg twice daily treatment phase (day 1&nbsp;-&nbsp;21), the patient should take Roxban immediately to ensure intake of 30&nbsp;mg Roxban per day. In this case two 15&nbsp;mg tablets may be taken at once. The patient should continue with the regular 15&nbsp;mg twice daily intake as recommended on the following day.</p><p>&nbsp;</p><p>If a dose is missed during the once daily treatment phase, the patient should take Roxban immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p>&nbsp;</p><p><em>Converting from Vitamin&nbsp;K Antagonists (VKA) to Roxban</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prevention of stroke and systemic embolism:<br />VKA treatment should be stopped and Roxban therapy should be initiated when the International Normalised Ratio (INR) is &le;&nbsp;3.0.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of DVT, PE and prevention of recurrence:<br />VKA treatment should be stopped and Roxban therapy should be initiated once the INR is &le;&nbsp;2.5.</p><p>When converting patients from VKAs to Roxban, INR values will be falsely elevated after the intake of Roxban. The INR is not valid to measure the anticoagulant activity of Roxban, and therefore should not be used (see section&nbsp;4.5).</p><p>&nbsp;</p><p><em>Converting from Roxban to Vitamin&nbsp;K antagonists (VKA)</em></p><p>There is a potential for inadequate anticoagulation during the transition from Roxban to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Roxban can contribute to an elevated INR.</p><p>In patients converting from Roxban to VKA, VKA should be given concurrently until the INR is &ge;&nbsp;2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Roxban and VKA the INR should not be tested earlier than 24&nbsp;hours after the previous dose but prior to the next dose of Roxban. Once Roxban is discontinued INR testing may be done reliably at least 24&nbsp;hours after the last dose (see sections&nbsp;4.5 and 5.2).</p><p>&nbsp;</p><p><em>Converting from parenteral anticoagulants to Roxban</em></p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Roxban 0 to 2&nbsp;hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p>&nbsp;</p><p><em>Converting from Roxban to parenteral anticoagulants</em></p><p>Discontinue Roxban and give the first dose of parenteral anticoagulant at the time the next Roxban dose would be taken.</p><p><u>&nbsp;</u></p><p><em>Special populations</em></p><p><em><u>Renal impairment</u></em></p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15&nbsp;-&nbsp;29&nbsp;ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Roxban is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt;&nbsp;15&nbsp;ml/min (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p>In patients with moderate (creatinine clearance 30&nbsp;-&nbsp;49&nbsp;ml/min) or severe (creatinine clearance 15-29&nbsp;ml/min) renal impairment the following dose recommendations apply:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the recommended dose is 15&nbsp;mg once daily (see section&nbsp;5.2).<br />&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE: patients should be treated with 15&nbsp;mg twice daily for the first 3&nbsp;weeks. Thereafter, when the recommended dose is 20&nbsp;mg once daily, a reduction of the dose from 20&nbsp;mg once daily to 15&nbsp;mg once daily should be considered if the patient&rsquo;s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15&nbsp;mg is based on PK modelling and has not been studied in this clinical setting (see sections&nbsp;4.4, 5.1 and 5.2).</p><p>When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.</p><p>&nbsp;</p><p>No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50&nbsp;‑&nbsp;80&nbsp;ml/min) (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Roxban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh&nbsp;B and C (see sections&nbsp;4.3 and 5.2).</p><p><strong><em>&nbsp;</em></strong></p><p><em><u>Elderly population</u></em></p><p>No dose adjustment (see section&nbsp;5.2)</p><p>&nbsp;</p><p><em><u>Body weight</u></em></p><p>No dose adjustment (see section&nbsp;5.2)</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>No dose adjustment (see section&nbsp;5.2)</p><p>&nbsp;</p><p><em><u>Patients undergoing cardioversion</u></em></p><p>Roxban can be initiated or continued in patients who may require cardioversion.<br />For transesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Roxban treatment should be started at least 4&nbsp;hours before cardioversion to ensure adequate anticoagulation (see sections&nbsp;5.1 and 5.2). For all patients, confirmation should be sought prior to cardioversion that the patient has taken Roxban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.</p><p>&nbsp;</p><p><em><u>Patients with non-valvular atrial fibrillation who undergo PCI (percutaneous coronary intervention) with stent placement</u></em></p><p>There is limited experience of a reduced dose of 15&nbsp;mg Roxban once daily (or 10&nbsp;mg Roxban once daily for patients with moderate renal impairment [creatinine clearance 30&nbsp;-&nbsp;49&nbsp;ml/min]) in addition to a P2Y12 inhibitor for a maximum of 12&nbsp;months in patients with non-valvular atrial fibrillation who require oral anticoagulation and undergo PCI with stent placement (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of Roxban in children aged 0 to &lt;&nbsp;18&nbsp;years have not been established in the indication prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. No data are available. Therefore, it is not recommended for use in children below 18&nbsp;years of age in indications other than the treatment of VTE and prevention of VTE recurrence.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Roxban is for oral use.</p><p>The tablets are to be taken with food (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Crushing of tablets</u></em></p><p>For patients who are unable to swallow whole tablets, Roxban tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed Roxban 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.</p><p>The crushed tablet may also be given through gastric tubes (see sections&nbsp;5.2 and&nbsp;6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active clinically significant bleeding. Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5). Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2). Pregnancy and breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p>&nbsp;</p><p><u>Haemorrhagic risk</u></p><p>As with other anticoagulants, patients taking Roxban are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Roxban administration should be discontinued if severe haemorrhage occurs (see section&nbsp;4.9).</p><p>&nbsp;</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.</p><p>&nbsp;</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section&nbsp;4.8).</p><p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>&nbsp;</p><p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In patients with severe renal impairment (creatinine clearance &lt;&nbsp;30&nbsp;ml/min) rivaroxaban plasma levels may be significantly increased (1.6&nbsp;fold on average) which may lead to an increased bleeding risk. Roxban is to be used with caution in patients with creatinine clearance 15&nbsp;-&nbsp;29&nbsp;ml/min. Use is not recommended in patients with creatinine clearance &lt;&nbsp;15&nbsp;ml/min (see sections&nbsp;4.2 and 5.2).</p><p>Roxban should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Interaction with other medicinal products</u></p><p>The use of Roxban is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6&nbsp;fold on average) which may lead to an increased bleeding risk (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered<em>&nbsp;</em>(see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Other haemorrhagic risk factors</u></p><p>As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;congenital or acquired bleeding disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;uncontrolled severe arterial hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vascular retinopathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bronchiectasis or history of pulmonary bleeding</p><p><u>&nbsp;</u></p><p><u>Patients with cancer</u></p><p>Patients with malignant disease may simultaneously be at higher risk of bleeding and thrombosis. The individual benefit of antithrombotic treatment should be weighed against risk for bleeding in patients with active cancer dependent on tumour location, antineoplastic therapy and stage of disease. Tumours located in the gastrointestinal or genitourinary tract have been associated with an increased risk of bleeding during rivaroxaban therapy.</p><p>In patients with malignant neoplasms at high risk of bleeding, the use of rivaroxaban is contraindicated (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Patients with prosthetic valves</u></p><p>Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR). Safety and efficacy of Roxban have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Roxban provides adequate anticoagulation in this patient population. Treatment with Roxban is not recommended for these patients.</p><p>&nbsp;</p><p><u>Patients with antiphospholipid syndrome</u></p><p>Direct acting Oral Anticoagulants (DOACs) including rivaroxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti‑beta&nbsp;2‑glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p>&nbsp;</p><p><u>Patients with non-valvular atrial fibrillation<em>&nbsp;</em>who undergo PCI with stent placement</u></p><p>Clinical data are available from an interventional study with the primary objective to assess safety in patients with non-valvular atrial fibrillation who undergo PCI with stent placement. Data on efficacy in this population are limited (see sections&nbsp;4.2 and 5.1). No data are available for such patients with a history of stroke/ transient ischaemic attack (TIA).</p><p>&nbsp;</p><p><u>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</u></p><p>Roxban is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Roxban have not been established in these clinical situations.</p><p>&nbsp;</p><p><u>Spinal/epidural anaesthesia or puncture</u></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of 15&nbsp;mg rivaroxaban in these situations.</p><p>To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known and should be weighed against the urgency of a diagnostic procedure.</p><p>For the removal of an epidural catheter and based on the general PK characteristics at least 2x&nbsp;half-life, i.e. at least 18&nbsp;hours in young patients and 26&nbsp;hours in elderly patients should elapse after the last administration of rivaroxaban (see section&nbsp;5.2). Following removal of the catheter, at least 6&nbsp;hours should elapse before the next rivaroxaban dose is administered.</p><p>If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24&nbsp;hours.</p><p><u>&nbsp;</u></p><p><u>Dosing recommendations before and after invasive procedures and surgical intervention</u></p><p>If an invasive procedure or surgical intervention is required, Roxban&nbsp;15&nbsp;mg should be stopped at least 24&nbsp;hours before the intervention, if possible and based on the clinical judgement of the physician.</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>Roxban should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>Increasing age may increase haemorrhagic risk (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Dermatological reactions</u></p><p>Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section&nbsp;4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p><p>&nbsp;</p><p><u>Information about excipients</u></p><p>Roxban contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.5. Interactions with other medicinal products</p><p>&nbsp;</p><p><u>CYP3A4 and P-gp inhibitors</u></p><p>Co-administration of rivaroxaban with ketoconazole (400&nbsp;mg once a day) or ritonavir (600&nbsp;mg twice a day) led to a 2.6&nbsp;fold&nbsp;/ 2.5&nbsp;fold increase in mean rivaroxaban AUC and a 1.7&nbsp;fold&nbsp;/ 1.6&nbsp;fold increase in mean rivaroxaban C<sub>max</sub>, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Roxban is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500&nbsp;mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5&nbsp;fold increase in mean rivaroxaban AUC and a 1.4&nbsp;fold increase in C<sub>max</sub>. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section&nbsp;4.4).</p><p>&nbsp;</p><p>Erythromycin (500&nbsp;mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3&nbsp;fold increase in mean rivaroxaban AUC and C<sub>max</sub>. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>In subjects with mild renal impairment erythromycin (500&nbsp;mg three times a day) led to a 1.8&nbsp;fold increase in mean rivaroxaban AUC and 1.6&nbsp;fold increase in C<sub>max</sub>&nbsp;when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0&nbsp;fold increase in mean rivaroxaban AUC and 1.6&nbsp;fold increase in C<sub>max</sub>&nbsp;when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Fluconazole (400&nbsp;mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4&nbsp;fold increase in mean rivaroxaban AUC and a 1.3&nbsp;fold increase in mean C<sub>max</sub>. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section&nbsp;4.4).</p><p>&nbsp;</p><p>Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>After combined administration of enoxaparin (40&nbsp;mg single dose) with rivaroxaban (10&nbsp;mg single dose) an additive effect on anti-factor&nbsp;Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections&nbsp;4.3 and 4.4).</p><p>&nbsp;</p><p><u>NSAIDs/platelet aggregation inhibitors</u></p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15&nbsp;mg) and 500&nbsp;mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500&nbsp;mg acetylsalicylic acid.</p><p>Clopidogrel (300&nbsp;mg loading dose followed by 75&nbsp;mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15&nbsp;mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>SSRIs/SNRIs</u></p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.</p><p>&nbsp;</p><p><u>Warfarin</u></p><p>Converting patients from the vitamin&nbsp;K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20&nbsp;mg) or from rivaroxaban (20&nbsp;mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.</p><p>If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.</p><p>If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the C<sub>trough</sub>&nbsp;of rivaroxaban (24&nbsp;hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and rivaroxaban.</p><p>&nbsp;</p><p><u>CYP3A4 inducers</u></p><p>Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&rsquo;s Wort&nbsp;<em>(Hypericum perforatum)</em>) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p>&nbsp;</p><p><u>Other concomitant therapies</u></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.</p><p>&nbsp;</p><p><u>Laboratory parameters</u></p><p>Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.6. Fertility, pregnancy and lactation</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Safety and efficacy of Roxban have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Roxban is contraindicated during pregnancy (see section&nbsp;4.3).</p><p>Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Safety and efficacy of Roxban have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Roxban is contraindicated during breast-feeding (see section&nbsp;4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.</p><p><em><u>&nbsp;</u></em></p><p><u>Fertility</u></p><p>No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.7. Effects on ability to drive and use machines</p><p>&nbsp;</p><p>Roxban has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section&nbsp;4.8). Patients experiencing these adverse reactions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.8. Undesirable effects</p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>The safety of rivaroxaban has been evaluated in thirteen pivotal phase&nbsp;III studies (see Table&nbsp;1).</p><p>&nbsp;</p><p>Overall, 69,608&nbsp;patients in nineteen phase III studies were exposed to rivaroxaban.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Number of patients studied, total daily dose and maximum treatment duration in&nbsp; phase&nbsp;III studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients*</strong></p></td><td style="vertical-align:top"><p><strong>Total daily dose</strong></p></td><td style="vertical-align:top"><p><strong>Maximum treatment duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td style="vertical-align:top"><p>6,097</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>39 days</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of VTE in medically ill patients</p></td><td style="vertical-align:top"><p>3,997</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>39 days</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrence</p></td><td style="vertical-align:top"><p>6,790</p></td><td style="vertical-align:top"><p>Day 1 - 21: 30 mg</p><p>Day 22 and onwards: 20 mg</p><p>After at least 6 months: 10 mg or 20 mg</p></td><td style="vertical-align:top"><p>21 months</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>7,750</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>41 months</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td style="vertical-align:top"><p>10,225</p></td><td style="vertical-align:top"><p>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td style="vertical-align:top"><p>31 months</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td style="vertical-align:top"><p>18,244</p></td><td style="vertical-align:top"><p>5 mg co-administered with ASA or 10 mg alone</p></td><td style="vertical-align:top"><p>47 months</p></td></tr><tr><td style="vertical-align:top"><p>3,256**</p></td><td style="vertical-align:top"><p>5 mg co-administered with ASA</p></td><td style="vertical-align:top"><p>42 months</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* Patients exposed to at least one dose of rivaroxaban</p><p>** From the VOYAGER PAD study</p></td></tr></tbody></table><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section&nbsp;4.4. and &lsquo;Description of selected adverse reactions&rsquo; below) (Table&nbsp;2). The most commonly reported bleedings were epistaxis (4.5&nbsp;%) and gastrointestinal tract haemorrhage (3.8&nbsp;%).</p><p><strong>Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed adult and paediatric phase III studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Any bleeding</strong></p></td><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td style="vertical-align:top"><p>6.8% of patients</p></td><td style="vertical-align:top"><p>5.9% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism in medically ill patients</p></td><td style="vertical-align:top"><p>12.6% of patients</p></td><td style="vertical-align:top"><p>2.1% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of DVT, PE and prevention of recurrence</p></td><td style="vertical-align:top"><p>23% of patients</p></td><td style="vertical-align:top"><p>1.6% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>28 per 100 patient years</p></td><td style="vertical-align:top"><p>2.5 per 100 patient years</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td style="vertical-align:top"><p>22 per 100 patient years</p></td><td style="vertical-align:top"><p>1.4 per 100 patient years</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td style="vertical-align:top"><p>6.7 per 100 patient years</p></td><td style="vertical-align:top"><p>0.15 per 100 patient years**</p></td></tr><tr><td style="vertical-align:top"><p>8.38 per 100 patient years&nbsp;#</p></td><td style="vertical-align:top"><p>0.74 per 100 patient years***&nbsp;#</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.</p><p>** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied</p><p>*** A selective approach to adverse event collection was applied</p><p># From the VOYAGER PAD study</p></td></tr></tbody></table><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions reported with Roxban are summarised in Table&nbsp;3 below by system organ class (in MedDRA) and by frequency.</p><p>&nbsp;</p><p>Frequencies are defined as:</p><p>very common (&ge;&nbsp;1/10)<br />common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10)<br />uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100)<br />rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)<br />very rare (&lt;&nbsp;1/10,000)</p><p>not known (cannot be estimated from the available data)</p><p><strong>Table 3: All adverse reactions reported in adult patients in phase III clinical studies or through post-marketing use* and in two phase II and two phase III studies in paediatric patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia (incl. respective laboratory parameters)</p></td><td style="vertical-align:top"><p>Thrombocytosis (incl. platelet count increased)A, thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction, dermatitis allergic, angioedema and allergic oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reactions including anaphylactic shock</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness, headache</p></td><td style="vertical-align:top"><p>Cerebral and intracranial haemorrhage, syncope</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eye haemorrhage (incl. conjunctival haemorrhage)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension, haematoma</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis, haemoptysis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eosinophilic pneumonia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation<sup>A</sup>, diarrhoea, vomiting<sup>A</sup></p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increase in transaminases</p></td><td style="vertical-align:top"><p>Hepatic impairment, increased bilirubin, increased blood alkaline phosphatase<sup>A</sup>, increased GGT<sup>A</sup></p></td><td style="vertical-align:top"><p>Jaundice, bilirubin conjugated increased (with or without concomitant increase of ALT), cholestasis, hepatitis (incl. hepatocellular injury)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome/Toxic Epidermal Necrolysis, DRESS syndrome</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity<sup>A</sup></p></td><td style="vertical-align:top"><p>Haemarthrosis</p></td><td style="vertical-align:top"><p>Muscle haemorrhage</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urogenital tract haemorrhage (incl. haematuria and menorrhagia<sup>B</sup>), renal impairment (incl. blood creatinine increased, blood urea increased)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fever<sup>A</sup>, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</p></td><td style="vertical-align:top"><p>Feeling unwell (incl. malaise)</p></td><td style="vertical-align:top"><p>Localised oedema<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increased LDH<sup>A</sup>, increased lipase<sup>A</sup>, increased amylase<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion<sup>A</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vascular pseudoaneurysm<sup>C</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</p><p>* A pre-specified selective approach to adverse event collection was applied in selected phase III studies. The incidence of adverse reactions did not increase and no new adverse drug reaction was identified after analysis of these studies.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Due to the pharmacological mode of action, the use of Roxban may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section&nbsp;4.9 &ldquo;Management of bleeding&rdquo;). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section&nbsp;4.4 &ldquo;Haemorrhagic risk&rdquo;). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence<em>&nbsp;</em>of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Roxban. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect id="Rectangle_x0020_1" o:spid="_x0000_s1027"
 style='position:absolute;left:0;text-align:left;margin-left:0;margin-top:22.1pt;
 width:512.45pt;height:133.85pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:center;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-height-percent:0;
 mso-height-relative:margin;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="black [3213]" strokeweight="1pt">
 <w:wrap anchorx="margin"/>
</v:rect><![endif]--><img width="685" height="181" src="file:///C:/Users/101623/AppData/Local/Packages/oice_16_974fa576_32c1d314_1561/AC/Temp/msohtmlclip1/01/clip_image001.png" /><strong>Saudi Arabia:</strong></p><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp;- Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&middot;</strong><strong> Other GCC States: </strong></p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_2" o:spid="_x0000_s1026"
 style='position:absolute;margin-left:-22pt;margin-top:17.25pt;width:512.45pt;
 height:42.35pt;z-index:251660288;visibility:visible;mso-wrap-style:square;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-height-percent:0;mso-height-relative:margin;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="black [3213]" strokeweight="1pt">
 <w:wrap anchorx="margin"/>
</v:rect><![endif]--><img width="685" height="59" src="file:///C:/Users/101623/AppData/Local/Packages/oice_16_974fa576_32c1d314_1561/AC/Temp/msohtmlclip1/01/clip_image002.png" /><strong>&nbsp;</strong></p><p>&nbsp;</p><p>- Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of overdose up to 1,960&nbsp;mg have been reported. In case of overdose, the patient should be observed carefully for bleeding complications or other adverse reactions (see section &ldquo;Management of bleeding&rdquo;). Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50&nbsp;mg rivaroxaban or above.</p><p>A specific reversal agent (andexanet alfa) antagonising the pharmacodynamic effect of rivaroxaban is available (refer to the Summary of Product Characteristics of andexanet alfa).</p><p>The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.</p><p><u>Management of bleeding</u></p><p>Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13&nbsp;hours (see section&nbsp;5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.</p><p>If bleeding cannot be controlled by the above measures, either the administration of a specific factor&nbsp;Xa&nbsp;inhibitor reversal agent (andexanet alfa), which antagonises the pharmacodynamic effect of rivaroxaban, or a specific procoagulant agent, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor&nbsp;VIIa (r-FVIIa), should be considered. However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor&nbsp;VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section&nbsp;5.1).</p><p>&nbsp;</p><p>Protamine sulphate and vitamin&nbsp;K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1. Pharmacodynamic Properties</p><p>&nbsp;</p><p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.</p><p>In patients receiving rivaroxaban for treatment of DVT and PE and prevention of recurrence, the 5/95 percentiles for PT (Neoplastin) 2&nbsp;-&nbsp;4&nbsp;hours after tablet intake (i.e. at the time of maximum effect) for 15&nbsp;mg rivaroxaban twice daily ranged from 17 to 32&nbsp;s and for 20&nbsp;mg rivaroxaban once daily from 15 to 30&nbsp;s. At trough (8&nbsp;-&nbsp;16&nbsp;h after tablet intake) the 5/95 percentiles for 15&nbsp;mg twice daily ranged from 14 to 24&nbsp;s and for 20&nbsp;mg once daily (18&nbsp;‑&nbsp;30&nbsp;h after tablet intake) from 13 to 20&nbsp;s.</p><p>In patients with non‑valvular atrial fibrillation receiving rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1&nbsp;-&nbsp;4&nbsp;hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20&nbsp;mg once daily ranged from 14 to 40&nbsp;s and in patients with moderate renal impairment treated with 15&nbsp;mg once daily from 10 to 50&nbsp;s. At trough (16&nbsp;-&nbsp;36&nbsp;h after tablet intake) the 5/95 percentiles in patients treated with 20&nbsp;mg once daily ranged from 12 to 26&nbsp;s and in patients with moderate renal impairment treated with 15&nbsp;mg once daily from 12 to 26&nbsp;s.</p><p>In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section&nbsp;4.9).</p><p>The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</u></em></p><p>The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.</p><p>In the pivotal double-blind ROCKET AF study, 14,264&nbsp;patients were assigned either to rivaroxaban 20&nbsp;mg once daily (15&nbsp;mg once daily in patients with creatinine clearance 30&nbsp;-&nbsp;49&nbsp;ml/min) or to warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0). The median time on treatment was 19&nbsp;months and overall treatment duration was up to 41&nbsp;months.</p><p>34.9% of patients were treated with acetylsalicylic acid and 11.4% were treated with class&nbsp;III antiarrhythmic including amiodarone.</p><p>&nbsp;</p><p>Rivaroxaban was non-inferior to warfarin for the primary composite endpoint of stroke and non-CNS systemic embolism. In the per-protocol population on treatment, stroke or systemic embolism occurred in 188&nbsp;patients on rivaroxaban (1.71% per year) and 241 on warfarin (2.16% per year) (HR&nbsp;0.79; 95%&nbsp;CI, 0.66&nbsp;-&nbsp;0.96; P&lt;0.001 for non-inferiority). Among all randomised patients analysed according to ITT, primary events occurred in 269 on rivaroxaban (2.12% per year) and 306 on warfarin (2.42% per year) (HR&nbsp;0.88; 95%&nbsp;CI, 0.74&nbsp;-&nbsp;1.03; P&lt;0.001 for non-inferiority; P=0.117 for superiority). Results for secondary endpoints as tested in hierarchical order in the ITT analysis are displayed in Table&nbsp;4.</p><p>Among patients in the warfarin group, INR values were within the therapeutic range (2.0 to 3.0) a mean of 55% of the time (median, 58%; interquartile range, 43 to 71). The effect of rivaroxaban did not differ across the level of centre TTR (Time in Target INR Range of 2.0&nbsp;-&nbsp;3.0) in the equally sized quartiles (P=0.74 for interaction). Within the highest quartile according to centre, the Hazard Ratio (HR) with rivaroxaban versus warfarin was 0.74 (95%&nbsp;CI, 0.49&nbsp;-&nbsp;1.12).</p><p>The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (see Table&nbsp;5).</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Efficacy results from phase&nbsp;III ROCKET AF</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>ITT analyses of efficacy in patients with non-valvular atrial fibrillation</strong></p></td></tr><tr><td><p><strong>Treatment dose</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban 20 mg once daily</strong></p><p><strong>(15 mg once daily in patients with moderate renal impairment)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td style="vertical-align:top"><p><strong>Warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td><p><strong>HR (95% CI)</strong></p><p><strong>p-value, test for superiority</strong></p></td></tr><tr><td><p>Stroke and non-CNS systemic embolism</p></td><td style="vertical-align:top"><p>269</p><p>(2.12)</p></td><td style="vertical-align:top"><p>306</p><p>(2.42)</p></td><td style="vertical-align:top"><p>0.88 (0.74 - 1.03)</p><p>0.117</p></td></tr><tr><td><p>Stroke, non-CNS systemic embolism and vascular death</p></td><td style="vertical-align:top"><p>572</p><p>(4.51)</p></td><td style="vertical-align:top"><p>609</p><p>(4.81)</p></td><td style="vertical-align:top"><p>0.94 (0.84 - 1.05)</p><p>0.265</p></td></tr><tr><td><p>Stroke, non-CNS systemic embolism, vascular death and myocardial infarction</p></td><td style="vertical-align:top"><p>659</p><p>(5.24)</p></td><td style="vertical-align:top"><p>709</p><p>(5.65)</p></td><td style="vertical-align:top"><p>0.93 (0.83 - 1.03)</p><p>0.158</p></td></tr><tr><td><p>Stroke</p></td><td style="vertical-align:top"><p>253</p><p>(1.99)</p></td><td style="vertical-align:top"><p>281</p><p>(2.22)</p></td><td style="vertical-align:top"><p>0.90 (0.76 - 1.07)</p><p>0.221</p></td></tr><tr><td><p>Non-CNS systemic embolism</p></td><td style="vertical-align:top"><p>20</p><p>(0.16)</p></td><td style="vertical-align:top"><p>27</p><p>(0.21)</p></td><td style="vertical-align:top"><p>0.74 (0.42 - 1.32)</p><p>0.308</p></td></tr><tr><td><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>130</p><p>(1.02)</p></td><td style="vertical-align:top"><p>142</p><p>(1.11)</p></td><td style="vertical-align:top"><p>0.91 (0.72 - 1.16)</p><p>0.464</p></td></tr></tbody></table><p><strong>Table 5: Safety results from phase III ROCKET AF</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="4"><p><strong>Patients with non-valvular atrial fibrillation<sup>a)</sup></strong></p></td></tr><tr><td><p><strong>Treatment dose</strong></p></td><td><p><strong>Rivaroxaban 20 mg once daily</strong></p><p><strong>(15 mg once daily in patients with moderate renal impairment)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td><p><strong>Warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td colspan="2"><p><strong>HR (95% CI)</strong></p><p><strong>p-value</strong></p></td></tr><tr><td><p>Major and non-major clinically relevant bleeding events</p></td><td><p>1,475</p><p>(14.91)</p></td><td><p>1,449</p><p>(14.52)</p></td><td colspan="2"><p>1.03 (0.96 - 1.11)</p><p>0.442</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>395</p><p>(3.60)</p></td><td><p>386</p><p>(3.45)</p></td><td colspan="2"><p>1.04 (0.90 - 1.20)</p><p>0.576</p></td></tr><tr><td><p>Death due to bleeding*</p></td><td style="vertical-align:top"><p>27</p><p>(0.24)</p></td><td style="vertical-align:top"><p>55</p><p>(0.48)</p></td><td colspan="2" style="vertical-align:top"><p>0.50 (0.31 - 0.79)</p><p>0.003</p></td></tr><tr><td><p>Critical organ bleeding*</p></td><td style="vertical-align:top"><p>91</p><p>(0.82)</p></td><td style="vertical-align:top"><p>133</p><p>(1.18)</p></td><td colspan="2" style="vertical-align:top"><p>0.69 (0.53 - 0.91)</p><p>0.007</p></td></tr><tr><td><p>Intracranial haemorrhage*</p></td><td style="vertical-align:top"><p>55</p><p>(0.49)</p></td><td style="vertical-align:top"><p>84</p><p>(0.74)</p></td><td colspan="2" style="vertical-align:top"><p>0.67 (0.47 - 0.93)</p><p>0.019</p></td></tr><tr><td><p>Haemoglobin drop*</p></td><td style="vertical-align:top"><p>305</p><p>(2.77)</p></td><td style="vertical-align:top"><p>254</p><p>(2.26)</p></td><td colspan="2" style="vertical-align:top"><p>1.22 (1.03 - 1.44)</p><p>0.019</p></td></tr><tr><td><p>Transfusion of 2 or more units of packed red blood cells or whole blood*</p></td><td style="vertical-align:top"><p>183</p><p>(1.65)</p></td><td style="vertical-align:top"><p>149</p><p>(1.32)</p></td><td colspan="2" style="vertical-align:top"><p>1.25 (1.01 - 1.55)</p><p>0.044</p></td></tr><tr><td><p>Non-major clinically relevant bleeding events</p></td><td><p>1,185</p><p>(11.80)</p></td><td><p>1,151</p><p>(11.37)</p></td><td colspan="2"><p>1.04 (0.96 - 1.13)</p><p>0.345</p></td></tr><tr><td><p>All-cause mortality</p></td><td><p>208</p><p>(1.87)</p></td><td><p>250</p><p>(2.21)</p></td><td colspan="2"><p>0.85 (0.70 - 1.02)</p><p>0.073</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a) Safety population, on treatment</p><p>* Nominally significant</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>In addition to the phase&nbsp;III ROCKET AF study, a prospective, single-arm, post-authorisation, non-interventional, open-label cohort study (XANTUS) with central outcome adjudication including thromboembolic events and major bleeding has been conducted. 6,704&nbsp;patients with non-valvular atrial fibrillation were enrolled for prevention of stroke and non-central nervous system (CNS) systemic embolism in clinical practice. The mean CHADS<sub>2</sub>&nbsp;score was 1.9 and HAS-BLED score was 2.0 in XANTUS, compared to a mean CHADS<sub>2</sub>&nbsp;and HAS-BLED score of 3.5 and 2.8 in ROCKET AF, respectively. Major bleeding occurred in 2.1 per 100&nbsp;patient years. Fatal haemorrhage was reported in 0.2 per 100&nbsp;patient years and intracranial haemorrhage in 0.4 per 100&nbsp;patient years. Stroke or non-CNS systemic embolism was recorded in 0.8 per 100&nbsp;patient years.</p><p>These observations in clinical practice are consistent with the established safety profile in this indication.</p><p>&nbsp;</p><p>In a post-authorisation, non-interventional study, in more than 162,000&nbsp;patients from four countries, rivaroxaban was prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The event rate for ischaemic stroke was 0.70 (95%&nbsp;CI 0.44&nbsp;-&nbsp;1.13) per 100&nbsp;patient-years. Bleeding resulting in hospitalisation occurred at event rates per 100&nbsp;patient-years of 0.43 (95%&nbsp;CI 0.31&nbsp;-&nbsp;0.59) for intracranial bleeding, 1.04 (95%&nbsp;CI 0.65&nbsp;-&nbsp;1.66) for gastrointestinal bleeding, 0.41 (95%&nbsp;CI 0.31&nbsp;-&nbsp;0.53) for urogenital bleeding and 0.40 (95%&nbsp;CI 0.25&nbsp;-&nbsp;0.65) for other bleeding.</p><p>&nbsp;</p><p><em>Patients undergoing cardioversion</em></p><p>A prospective, randomised, open-label, multicentre, exploratory study with blinded endpoint evaluation (X-VERT) was conducted in 1504&nbsp;patients (oral anticoagulant naive and pre-treated) with non-valvular atrial fibrillation scheduled for cardioversion to compare rivaroxaban with dose-adjusted VKA (randomised 2:1), for the prevention of cardiovascular events. TEE- guided (1&nbsp;-&nbsp;5 days of pre-treatment) or conventional cardioversion (at least three weeks of pre-treatment) strategies were employed. The primary efficacy outcome (all stroke, transient ischaemic attack, non-CNS systemic embolism, myocardial infarction (MI) and cardiovascular death) occurred in 5 (0.5%) patients in the rivaroxaban group (n&nbsp;=&nbsp;978) and 5 (1.0%) patients in the VKA group (n&nbsp;=&nbsp;492; RR 0.50; 95%&nbsp;CI 0.15-1.73; modified ITT population). The principal safety outcome (major bleeding) occurred in 6 (0.6%) and 4 (0.8%) patients in the rivaroxaban (n&nbsp;=&nbsp;988) and VKA (n&nbsp;=&nbsp;499) groups, respectively (RR&nbsp;0.76; 95%&nbsp;CI 0.21-2.67; safety population). This exploratory study showed comparable efficacy and safety between rivaroxaban and VKA treatment groups in the setting of cardioversion.</p><p><u>&nbsp;</u></p><p><em>Patients with non-valvular atrial fibrillation who undergo PCI with stent placement</em></p><p>A randomised, open-label, multicentre study (PIONEER AF-PCI) was conducted in 2,124&nbsp;patients with non-valvular atrial fibrillation who underwent PCI with stent placement for primary atherosclerotic disease to compare safety of two rivaroxaban regimens and one VKA regimen. Patients were randomly assigned in a 1:1:1 fashion for an overall 12-month-therapy. Patients with a history of stroke or TIA were excluded.</p><p>Group 1 received rivaroxaban 15 mg once daily (10 mg once daily in patients with creatinine clearance 30&nbsp;-&nbsp;49&nbsp;ml/min) plus P2Y12 inhibitor. Group 2 received rivaroxaban 2.5&nbsp;mg twice daily plus DAPT (dual antiplatelet therapy i.e. clopidogrel 75&nbsp;mg [or alternate P2Y12 inhibitor] plus low-dose acetylsalicylic acid [ASA]) for 1, 6 or 12 months followed by rivaroxaban 15&nbsp;mg (or 10&nbsp;mg for subjects with creatinine clearance 30&nbsp;-&nbsp;49&nbsp;ml/min) once daily plus low-dose ASA. Group 3 received dose-adjusted VKA plus DAPT for 1, 6 or 12&nbsp;months followed by dose-adjusted VKA plus low-dose ASA.</p><p>The primary safety endpoint, clinically significant bleeding events, occurred in 109 (15.7%), 117 (16.6%), and 167 (24.0%) subjects in group 1, group 2 and group 3, respectively (HR 0.59; 95% CI 0.47-0.76; p&lt;0.001, and HR 0.63; 95% CI 0.50-0.80; p&lt;0.001, respectively). The secondary endpoint (composite of cardiovascular events CV death, MI, or stroke) occurred in 41 (5.9%), 36 (5.1%), and 36 (5.2%) subjects in the group 1, group 2 and group 3, respectively. Each of the rivaroxaban regimens showed a significant reduction in clinically significant bleeding events compared to the VKA regimen in patients with non-valvular atrial fibrillation who underwent a PCI with stent placement.</p><p>The primary objective of PIONEER AF-PCI was to assess safety. Data on efficacy (including thromboembolic events) in this population are limited.</p><p>&nbsp;</p><p><em><u>Treatment of DVT, PE and prevention of recurrent DVT and PE</u></em></p><p>The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban in the initial and continued treatment of acute DVT and PE and prevention of recurrence.</p><p>Over 12,800 patients were studied in four randomised controlled phase&nbsp;III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21&nbsp;months.</p><p>&nbsp;</p><p>In Einstein DVT 3,449&nbsp;patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12&nbsp;months depending on the clinical judgement of the investigator.</p><p>For the initial 3&nbsp;week treatment of acute DVT 15&nbsp;mg rivaroxaban was administered twice daily. This was followed by 20&nbsp;mg rivaroxaban once daily.</p><p>&nbsp;</p><p>In Einstein PE, 4,832&nbsp;patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12&nbsp;months depending on the clinical judgement of the investigator.</p><p>For the initial treatment of acute PE 15&nbsp;mg rivaroxaban was administered twice daily for three weeks. This was followed by 20&nbsp;mg rivaroxaban once daily.</p><p>&nbsp;</p><p>In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5&nbsp;days in combination with vitamin&nbsp;K antagonist treatment until the PT/INR was in therapeutic range (&sup3;&nbsp;2.0). Treatment was continued with a vitamin&nbsp;K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.</p><p>&nbsp;</p><p>In Einstein Extension 1,197&nbsp;patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12&nbsp;months in patients who had completed 6 to 12&nbsp;months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Rivaroxaban 20&nbsp;mg once daily was compared with placebo.</p><p>&nbsp;</p><p>Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.</p><p>&nbsp;</p><p>In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Rivaroxaban 20&nbsp;mg once daily and rivaroxaban 10&nbsp;mg once daily were compared with 100&nbsp;mg acetylsalicylic acid once daily.</p><p>The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.</p><p>&nbsp;</p><p>In the Einstein DVT study (see<em>&nbsp;</em>Table&nbsp;6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p&nbsp;&lt;&nbsp;0.0001 (test for non-inferiority); HR: 0.680 (0.443&nbsp;‑&nbsp;1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95%&nbsp;CI:&nbsp;0.47&nbsp;-&nbsp;0.95), nominal p&nbsp;value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189&nbsp;days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0&nbsp;-&nbsp;3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95%&nbsp;CI: 0.35&nbsp;-&nbsp;1.35).</p><p>&nbsp;</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Efficacy and safety results from phase&nbsp;III Einstein DVT</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>3,449 patients with symptomatic acute deep vein thrombosis</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban&nbsp;<sup>a)</sup></strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=1,731</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=1,718</strong></p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>36</p><p>(2.1%)</p></td><td><p>51</p><p>(3.0%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>20</p><p>(1.2%)</p></td><td><p>18</p><p>(1.0%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>28</p><p>(1.6%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1</p><p>(0.1%)</p></td><td><p>0</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>4</p><p>(0.2%)</p></td><td><p>6</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>139</p><p>(8.1%)</p></td><td><p>138</p><p>(8.1%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>20</p><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>*</strong>&nbsp;p &lt; 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)</p></td></tr></tbody></table><p>&nbsp;</p><p>In the Einstein PE study (see<em>&nbsp;</em>Table&nbsp;7) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR:&nbsp;1.123 (0.749&nbsp;-&nbsp;1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95%&nbsp;CI:&nbsp;0.633&nbsp;- 1.139), nominal p&nbsp;value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215&nbsp;days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0&nbsp;-&nbsp;3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.642 (95%&nbsp;CI: 0.277&nbsp;-&nbsp;1.484).</p><p>&nbsp;</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308&nbsp;-&nbsp;0.789).</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;7: Efficacy and safety results from phase&nbsp;III Einstein PE</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>4,832 patients with an acute symptomatic PE</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban&nbsp;<sup>a)</sup></strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=2,419</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=2,413</strong></p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>50</p><p>(2.1%)</p></td><td><p>44</p><p>(1.8%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>23</p><p>(1.0%)</p></td><td><p>20</p><p>(0.8%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>18</p><p>(0.7%)</p></td><td><p>17</p><p>(0.7%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>0</p></td><td><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>11</p><p>(0.5%)</p></td><td><p>7</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>249</p><p>(10.3%)</p></td><td><p>274</p><p>(11.4%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>26</p><p>(1.1%)</p></td><td><p>52</p><p>(2.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p>* p &lt; 0.0026 (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)</p></td></tr></tbody></table><p>A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (Table 8).</p><p><strong>Table 8: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>8,281 patients with an acute symptomatic DVT or PE</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban&nbsp;<sup>a)</sup></strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=4,150</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=4,131</strong></p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>86</p><p>(2.1%)</p></td><td><p>95</p><p>(2.3%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>43</p><p>(1.0%)</p></td><td><p>38</p><p>(0.9%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>32</p><p>(0.8%)</p></td><td><p>45</p><p>(1.1%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1</p><p>(&lt;0.1%)</p></td><td><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>15</p><p>(0.4%)</p></td><td><p>13</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>388</p><p>(9.4%)</p></td><td><p>412</p><p>(10.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>40</p><p>(1.0%)</p></td><td><p>72</p><p>(1.7%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>*</strong>&nbsp;p &lt; 0.0001 (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)</p></td></tr></tbody></table><p>The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95%&nbsp;CI:&nbsp;0.614&nbsp;- 0.967), nominal p&nbsp;value p= 0.0244).</p><p>&nbsp;</p><p>In the Einstein Extension study (see<em>&nbsp;</em>Table&nbsp;9) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20&nbsp;mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20&nbsp;mg once daily compared to placebo.</p><p>&nbsp;</p><p><strong>Table&nbsp;9: Efficacy and safety results from phase&nbsp;III Einstein Extension</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban&nbsp;<sup>a)</sup></strong></p><p><strong>6 or 12 months</strong></p><p><strong>N=602</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>6 or 12 months</strong></p><p><strong>N=594</strong></p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>8</p><p>(1.3%)</p></td><td><p>42</p><p>(7.1%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>2</p><p>(0.3%)</p></td><td><p>13</p><p>(2.2%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>5</p><p>(0.8%)</p></td><td><p>31</p><p>(5.2%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>1</p><p>(0.2%)</p></td><td><p>1</p><p>(0.2%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>4</p><p>(0.7%)</p></td><td><p>0</p><p>(0.0%)</p></td></tr><tr><td><p>Clinically relevant non-major bleeding</p></td><td><p>32</p><p>(5.4%)</p></td><td><p>7</p><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 20 mg once daily</p><p><strong>*</strong>&nbsp;p &lt; 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)</p></td></tr></tbody></table><p>In the Einstein Choice study (see Table 10) rivaroxaban 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with rivaroxaban 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.</p><p><strong>Table 10: Efficacy and safety results from phase III Einstein Choice</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>3,396 patients continued prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td><p><strong>Treatment dose</strong></p></td><td><p><strong>Rivaroxaban 20 mg once daily</strong></p><p><strong>N=1,107</strong></p></td><td><p><strong>Rivaroxaban 10 mg once daily</strong></p><p><strong>N=1,127</strong></p></td><td><p><strong>ASA 100 mg once daily</strong></p><p><strong>N=1,131</strong></p></td></tr><tr><td><p>Treatment duration median [interquartile range]</p></td><td><p>349 [189-362] days</p></td><td><p>353 [190-362] days</p></td><td><p>350 [186-362] days</p></td></tr><tr><td><p>Symptomatic recurrent VTE</p></td><td><p>17</p><p>(1.5%)*</p></td><td><p>13</p><p>(1.2%)**</p></td><td><p>50</p><p>(4.4%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>6</p><p>(0.5%)</p></td><td><p>6</p><p>(0.5%)</p></td><td><p>19</p><p>(1.7%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>9</p><p>(0.8%)</p></td><td><p>8</p><p>(0.7%)</p></td><td><p>30</p><p>(2.7%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>2</p><p>(0.2%)</p></td><td><p>0</p><p>(0.0%)</p></td><td><p>2</p><p>(0.2%)</p></td></tr><tr><td><p>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</p></td><td><p>19</p><p>(1.7%)</p></td><td><p>18</p><p>(1.6%)</p></td><td><p>56</p><p>(5.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>6</p><p>(0.5%)</p></td><td><p>5</p><p>(0.4%)</p></td><td><p>3</p><p>(0.3%)</p></td></tr><tr><td><p>Clinically relevant non-major bleeding</p></td><td><p>30</p><p>(2.7)</p></td><td><p>22</p><p>(2.0)</p></td><td><p>20</p><p>(1.8)</p></td></tr><tr><td><p>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</p></td><td><p>23</p><p>(2.1%)<sup>+</sup></p></td><td><p>17</p><p>(1.5%)<sup>++</sup></p></td><td><p>53</p><p>(4.7%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* &nbsp;&nbsp; p&lt;0.001(superiority) rivaroxaban 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)</p><p>** p&lt;0.001 (superiority) rivaroxaban 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)</p><p>+ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rivaroxaban 20&nbsp;mg od vs ASA 100&nbsp;mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)</p><p>++&nbsp;&nbsp; Rivaroxaban 10&nbsp;mg od vs ASA 100&nbsp;mg od; HR=0.32 (0.18-0.55), p&lt;0.0001 (nominal)</p></td></tr></tbody></table><p>&nbsp;</p><p>In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of Rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for Rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing Rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively.</p><p>These results in clinical practice are consistent with the established safety profile in this indication.</p><p><u>Paediatric population</u></p><p><em>Treatment of VTE and prevention of VTE recurrence in paediatric patients</em></p><p>A total of 727 children with confirmed acute VTE, of whom 528 received rivaroxaban, were studied in 6 open-label, multicentre paediatric studies. Body weight-adjusted dosing in patients from birth to less than 18 years resulted in rivaroxaban exposure similar to that observed in adult DVT patients treated with rivaroxaban 20 mg once daily as confirmed in the phase III study (see section 5.2).</p><p>The EINSTEIN Junior phase III study was a randomised, active-controlled, open-label multicentre clinical study in 500 paediatric patients (aged from birth to &lt; 18 years) with confirmed acute VTE. There were 276 children aged 12 to &lt; 18 years, 101 children aged 6 to &lt; 12 years, 69 children aged 2 to &lt; 6 years, and 54 children aged &lt; 2 years.</p><p>Index VTE was classified as either central venous catheter-related VTE (CVC-VTE; 90/335 patients in the rivaroxaban group, 37/165 patients in the comparator group), cerebral vein and sinus thrombosis (CVST; 74/335 patients in the rivaroxaban group, 43/165 patients in the comparator group), and all others including DVT and PE (non-CVC-VTE; 171/335 patients in the rivaroxaban group, 85/165 patients in the comparator group). The most common presentation of index thrombosis in children aged 12 to &lt; 18 years was non-CVC-VTE in 211 (76.4%); in children aged 6 to &lt; 12 years and aged 2 to &lt; 6 years was CVST in 48 (47.5%) and 35 (50.7%), respectively; and in children aged &lt; 2 years was CVC-VTE in 37 (68.5%). There were no children &lt; 6 months with CVST in the rivaroxaban group. 22 of the patients with CVST had a CNS infection (13 patients in the rivaroxaban group and 9 patients in comparator group).</p><p>VTE was provoked by persistent, transient, or both persistent and transient risk factors in 438 (87.6%) children.</p><p>Patients received initial treatment with therapeutic doses of UFH, LMWH, or fondaparinux for at least 5 days, and were randomised 2:1 to receive either body weight-adjusted doses of rivaroxaban or comparator group (heparins, VKA) for a main study treatment period of 3 months (1 month for children &lt; 2 years with CVC-VTE). At the end of the main study treatment period, the diagnostic imaging test, which was obtained at baseline, was repeated, if clinically feasible. The study treatment could be stopped at this point, or at the discretion of the Investigator continued for up to 12 months (for children &lt;2 years with CVC-VTE up to 3 months) in total.</p><p>The primary efficacy outcome was symptomatic recurrent VTE. The primary safety outcome was the composite of major bleeding and clinically relevant non-major bleeding (CRNMB). All efficacy and safety outcomes were centrally adjudicated by an independent committee blinded for treatment allocation. The efficacy and safety results are shown in Tables 11 and 12 below.</p><p>Recurrent VTEs occurred in the rivaroxaban group in 4 of 335 patients and in the comparator group in 5 of 165 patients. The composite of major bleeding and CRNMB was reported in 10 of 329 patients (3%) treated with rivaroxaban and in 3 of 162 patients (1.9%) treated with comparator. Net clinical benefit (symptomatic recurrent VTE plus major bleeding events) was reported in the rivaroxaban group in 4 of 335 patients and in the comparator group in 7 of 165 patients. Normalisation of the thrombus burden on repeat imaging occurred in 128 of 335 patients with rivaroxaban treatment and in 43 of 165 patients in the comparator group. These findings were generally similar among age groups. There were 119 (36.2%) children with any treatment-emergent bleeding in the rivaroxaban group and 45 (27.8%) children in the comparator group.</p><p><strong>Table 11: Efficacy results at the end of the main treatment period</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Event</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban</strong></p><p><strong>N=335*</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p><p><strong>N=165*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Recurrent VTE (primary efficacy outcome)</p></td><td style="vertical-align:top"><p>4</p><p>(1.2%, 95% CI 0.4% &ndash; 3.0%)</p></td><td style="vertical-align:top"><p>5</p><p>(3.0%, 95% CI 1.2% - 6.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Composite: Symptomatic recurrent VTE + asymptomatic deterioration on repeat imaging</p></td><td style="vertical-align:top"><p>5</p><p>(1.5%, 95% CI 0.6% &ndash; 3.4%)</p></td><td style="vertical-align:top"><p>6</p><p>(3.6%, 95% CI 1.6% &ndash; 7.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Composite: Symptomatic recurrent VTE + asymptomatic deterioration + no change on repeat imaging</p></td><td style="vertical-align:top"><p>21</p><p>(6.3%, 95% CI 4.0% &ndash; 9.2%)</p></td><td style="vertical-align:top"><p>19</p><p>(11.5%, 95% CI 7.3% &ndash; 17.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Normalisation on repeat imaging</p></td><td style="vertical-align:top"><p>128</p><p>(38.2%, 95% CI 33.0% - 43.5%)</p></td><td style="vertical-align:top"><p>43</p><p>(26.1%, 95% CI 19.8% - 33.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Composite: Symptomatic recurrent VTE + major bleeding (net clinical benefit)</p></td><td style="vertical-align:top"><p>4</p><p>(1.2%, 95% CI 0.4% - 3.0%)</p></td><td style="vertical-align:top"><p>7</p><p>(4.2%, 95% CI 2.0% - 8.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal or non-fatal pulmonary embolism</p></td><td style="vertical-align:top"><p>1</p><p>(0.3%, 95% CI 0.0% &ndash; 1.6%)</p></td><td style="vertical-align:top"><p>1</p><p>(0.6%, 95% CI 0.0% &ndash; 3.1%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* FAS= full analysis set, all children who were randomised</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 12: Safety results at the end of the main treatment period</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Rivaroxaban</strong></p><p><strong>N=329*</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p><p><strong>N=162*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Composite: Major bleeding + CRNMB (primary safety outcome)</p></td><td style="vertical-align:top"><p>10</p><p>(3.0%, 95% CI 1.6% - 5.5%)</p></td><td style="vertical-align:top"><p>3</p><p>(1.9%, 95% CI 0.5% - 5.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding</p></td><td style="vertical-align:top"><p>0</p><p>(0.0%, 95% CI 0.0% - 1.1%)</p></td><td style="vertical-align:top"><p>2</p><p>(1.2%, 95% CI 0.2% - 4.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Any treatment-emergent bleedings</p></td><td style="vertical-align:top"><p>119 (36.2%)</p></td><td style="vertical-align:top"><p>45 (27.8%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* SAF = safety analysis set, all children who were randomised and received at least 1 dose of study medicinal product</p></td></tr></tbody></table><p>The efficacy and safety profile of rivaroxaban was largely similar between the paediatric VTE population and the DVT/PE adult population, however, the proportion of subjects with any bleeding was higher in the paediatric VTE population as compared to the DVT/PE adult population.</p><p><em>Patients with high risk triple positive antiphospholipid syndrome</em></p><p>In an investigator sponsored, randomised open-label multicentre study with blinded endpoint adjudication, rivaroxaban was compared to warfarin in patients with a history of thrombosis, diagnosed with antiphospholipid syndrome and at high risk for thromboembolic events (positive for all 3 antiphospholipid tests: lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies). The study was terminated prematurely after the enrolment of 120 patients due to an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. 59 patients were randomised to rivaroxaban 20 mg (15 mg for patients with creatinine clearance (CrCl) &lt; 50 mL/min) and 61 to warfarin (INR 2.0-3.0). Thromboembolic events occurred in 12% of patients randomised to rivaroxaban (4 ischaemic strokes and 3 myocardial infarctions). No events were reported in patients randomised to warfarin. Major bleeding occurred in 4 patients (7%) of the rivaroxaban group and 2 patients (3%) of the warfarin group.</p><p><em>Paediatric population</em></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Rivaroxabanin all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>5.2 Pharmacokinetic properties</u></p><p><strong>Absorption</strong></p><p>The following information is based on the data obtained in adults.</p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (Cmax) appearing 2 - 4 hours after tablet intake.</p><p>Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or Cmax&nbsp;at the 2.5 mg and 10 mg dose.</p><p>Due to a reduced extent of absorption an oral bioavailability of 66% was determined for the 20 mg tablet under fasting conditions. When rivaroxaban 20 mg tablets are taken together with food increases in mean AUC by 39% were observed when compared to tablet intake under fasting conditions, indicating almost complete absorption and high oral bioavailability. Rivaroxaban 15 mg and 20 mg are to be taken with food (see section 4.2).</p><p>Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily in fasting state. Under fed conditions rivaroxaban 10 mg, 15 mg and 20 mg tablets demonstrated dose-proportionality. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.</p><p>Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.</p><p>Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and Cmax&nbsp;compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.</p><p>Bioavailability (AUC and Cmax) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.</p><p><em>Paediatric population</em></p><p>Children received rivaroxaban tablet or oral suspension during or closely after feeding or food intake and with a typical serving of liquid to ensure reliable dosing in children. As in adults, rivaroxaban is readily absorbed after oral administration as tablet or granules for oral suspension formulation in children. No difference in the absorption rate nor in the extent of absorption between the tablet and granules for oral suspension formulation was observed. No PK data following intravenous administration to children are available so that the absolute bioavailability of rivaroxaban in children is unknown. A decrease in the relative bioavailability for increasing doses (in mg/kg bodyweight) was found, suggesting absorption limitations for higher doses, even when taken together with food.</p><p>Rivaroxaban 20 mg tablets should be taken with feeding or with food (see section 4.2).</p><p>Rivaroxaban 15 mg tablets should be taken with feeding or with food (see section 4.2).</p><p><strong>Distribution</strong></p><p>Plasma protein binding in adults is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with Vss&nbsp;being approximately 50 litres.</p><p><em>Paediatric population</em></p><p>No data on rivaroxaban plasma protein binding specific to children is available. No PK data following intravenous administration of rivaroxaban to children is available. Vss&nbsp;estimated via population PK modelling in children (age range 0 to &lt; 18 years) following oral administration of rivaroxaban is dependent on body weight and can be described with an allometric function, with an average of 113 L for a subject with a body weight of 82.8 kg.</p><p><strong>Biotransformation and elimination</strong></p><p>In adults, of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on&nbsp;in vitro&nbsp;investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p><em>Paediatric population</em></p><p>No metabolism data specific to children is available. No PK data following intravenous administration of rivaroxaban to children is available. CL estimated via population PK modelling in children (age range 0 to &lt; 18 years) following oral administration of rivaroxaban is dependent on body weight and can be described with an allometric function, with an average of 8 L/h for a subject with body weight of 82.8 kg. The geometric mean values for disposition half-lives (t1/2) estimated via population PK modelling decrease with decreasing age and ranged from 4.2 h in adolescents to approximately 3 h in children aged 2-12 years down to 1.9 and 1.6 h in children aged 0.5-&lt; 2 years and less than 0.5 years, respectively.</p><p><u>Special populations</u></p><p><em>Gender</em></p><p>In adults, there were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients. An exploratory analysis did not reveal relevant differences in rivaroxaban exposure between male and female children.</p><p><em>Elderly population</em></p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p><em>Different weight categories</em></p><p>In adults, extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.</p><p>In children, rivaroxaban is dosed based on body weight. An exploratory analysis did not reveal a relevant impact of underweight or obesity on rivaroxaban exposure in children.</p><p><em>Inter-ethnic differences</em></p><p>In adults, no clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.</p><p>An exploratory analysis did not reveal relevant inter-ethnic differences in rivaroxaban exposure among Japanese, Chinese or Asian children outside Japan and China compared to the respective overall paediatric population.</p><p><em>Hepatic impairment</em></p><p>Cirrhotic adult patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.</p><p>Rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p>No clinical data is available in children with hepatic impairment.</p><p><em>Renal impairment</em></p><p>In adults, there was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Rivaroxaban is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p>No clinical data is available in children 1 year or older with moderate or severe renal impairment (glomerular filtration rate &lt; 50 mL/min/1.73 m2).</p><p><u>Pharmacokinetic data in patients</u></p><p>In patients receiving rivaroxaban for treatment of acute DVT 20 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 215 (22 - 535) and 32 (6 - 239) mcg/l, respectively.</p><p>In paediatric patients with acute VTE receiving body weight-adjusted rivaroxaban leading to an exposure similar to that in adult DVT patients receiving a 20 mg once daily dose, the geometric mean concentrations (90% interval) at sampling time intervals roughly representing maximum and minimum concentrations during the dose interval are summarised in Table 13.</p><p><strong>Table 13: Summary statistics (geometric mean (90% interval)) of rivaroxaban steady state plasma concentrations (mcg/L) by dosing regimen and age</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Time intervals</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>o.d.</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>12 -&lt; 18 years</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>6 -&lt; 12 years</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>2.5-4h post</p></td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>241.5</p><p>(105-484)</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>229.7</p><p>(91.5-777)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>20-24h post</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>20.6</p><p>(5.69-66.5)</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>15.9</p><p>(3.42-45.5)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>b.i.d.</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>6 -&lt; 12 years</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>2 -&lt; 6 years</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>0.5 -&lt; 2 years</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>2.5-4h post</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>145.4</p><p>(46.0-343)</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>171.8</p><p>(70.7-438)</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>n.c.</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>10-16h post</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>26.0</p><p>(7.99-94.9)</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>22.2</p><p>(0.25-127)</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>10.7</p><p>(n.c.-n.c.)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>t.i.d.</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>2 -&lt; 6 years</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Birth -&lt; 2 years</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>0.5 -&lt; 2 years</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Birth -&lt; 0.5 years</strong></p></td></tr><tr><td style="vertical-align:top"><p>0.5-3h post</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>164.7</p><p>(108-283)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>111.2</p><p>(22.9-320)</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>114.3</p><p>(22.9-346)</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>108.0</p><p>(19.2-320)</p></td></tr><tr><td style="vertical-align:top"><p>7-8h post</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>33.2</p><p>(18.7-99.7)</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>18.7</p><p>(10.1-36.5)</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>21.4</p><p>(10.5-65.6)</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>16.1</p><p>(1.03-33.6)</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p>o.d. = once daily, b.i.d. = twice daily, t.i.d. three times daily, n.c. = not calculated</p><p>Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 0.5 mcg/L).</p></td></tr></tbody></table><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an Emax&nbsp;model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.</p><p><em>Paediatric population</em></p><p>Safety and efficacy have not been established in the indication prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation for children and adolescents up to 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>5.3 Preclinical safety data</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.</p><p>Rivaroxaban was tested in juvenile rats up to 3-month treatment duration starting at postnatal day 4 showing a non dose-related increase in periinsular haemorrhage. No evidence of target organ-specific toxicity was seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roxban 15 mg Filmcoated Tablets:</p><p>Microcrystalline Cellulose, Croscarmellose sodium, Lactose Monohydrate, Hypromellose, Sodium Laurilsulfate, Magnesium Stearate, Coating material for 15 mg Opadry Red 03F250004.</p><p>Roxban 20 mg Filmcoated Tablets:</p><p>Microcrystalline Cellulose, Croscarmellose sodium, Lactose Monohydrate, Hypromellose, Sodium Laurilsulfate, Magnesium Stearate, Coating material for 20 mg Opadry Red 03F250005</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roxban 15 mg and 20 mg:</p><p>PVC/PE/PVDC White Opaque/ Aluminum Foil Blister of 15 tablets; cartons of 30 tablets (2 blisters)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                . MARKETING AUTHORISATION HOLDER
AJA PHARMA:
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>